UNSPSC 51343118: Lamivudine sulfoxide

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0EH965X85, chemically known as lamivudine sulfoxide, (3rs)-, but more generally known as lamivudine sulfoxide, which bears US NIH Compound Identifier 3081342. European Medicines Agency schedules lamivudine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG.

Most nations, for tariff purposes, schedule lamivudine sulfoxide under HS 29349990. SMILES: C1CN(C(=O)NC1N)[C@@H]2C[S+]([C@@H](O2)CO)[O-].

UNSPSC 51343118 Lamivudine sulfoxide is a Commodity code nominally tracking an antiretroviral pharmaceutical compound, but recent state and local procurement activity under this code shows negligible alignment with that product category. The four recent opportunities posted under or near this code — Seminole County's naloxone and drug deactivation systems, Texas HHS's direct-to-manufacturer prescription program RFI, Tampa's medical and first aid supplies for fire rescue, and Minnesota MMCAP's generic pharmaceuticals cooperative contract — address emergency medical supplies, broader pharmacy benefit management, and general medical consumables rather than lamivudine sulfoxide specifically. State and local purchasing offices have tagged these solicitations to the code without apparent regard for the pharmaceutical's therapeutic class or chemical identity, suggesting either data-entry error or overuse of a catch-all pharmaceutical commodity code by different jurisdictions.

Activity appears concentrated in a handful of states and regions. The most substantial recent opportunity is the Minnesota MMCAP generic pharmaceuticals RFP (S1070000015802, due March 26, 2026), a multistate cooperative purchasing vehicle administered through the Minnesota Department of Administration that serves state and local facilities across participating jurisdictions including Oregon. The City of Tampa issued an IFB for medical and first aid supplies (26P00145, due March 13, 2026) with an estimated value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises. Seminole County, Florida solicited naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries. Because the tagging of these opportunities to UNSPSC 51343118 does not reflect their actual scope, the code shows little relevant recent activity for vendors seeking to market lamivudine sulfoxide or similar antiretroviral compounds to state and local health agencies.